FoRx Therapeutics raises €42.0M Series A round

The funding will be used to advance Phase 1 clinical development of its lead drug candidate, FORX-428, a potential best-in-class PARG inhibitor designed to target and disrupt the DNA Damage Response (DDR) in advanced solid tumors, with initial clinical data expected in mid-2026.

Source: https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGrS7Tj2uOe_C-8B1lHyVcujFSe2E2k4vz6iJT2UMCqtK7sP9zewr5SelBTWAJLfRlO9YjqJ2oTpOLXQZ0ZV4JBJdgqxGOHH6nRI2vCUUzamlKvDSGuMVkeBkOCkVO-CIkcroOFSWhSOJvpUYXnvVcSZNb5FXQH1Dtrq67poUXRQHREbj8mdfZ0Lesty-WLx6m6lZjTS_ohjtC3LLk1Dkykmh1OKCkKFUfC-l0TA7mYW3BB6pXMC2dF9N5xnezTFlON8WrkUTuqCoeLHALjp5X7M0qXyN5zXT9-isBKK3Fb0dN-GROA